Cary Fukunaga, director of Netflix’s Maniac, says that he wouldn’t return for a second season.
Cary Fukunaga, the acclaimed director of True Detective season one and Beasts of No Nation, has had his latest effort, Maniac, recently arrive to Netflix. The show stars Jonah Hill and Emma Stone and has been positively received thus far.
However, the director says that if the show were to be picked up for a second season, he wouldn’t be interested in returning. Explaining his reasoning to Business Insider, Fukunaga said:
“For me, I like to do one and move onto something else. I’d be very happy if another season were to happen, but I think they were just thinking about this as a limited season and if there’s an appetite for another one then I think [show co-creator] Patrick [Somerville] would be happy to take it up and do it again. But not with me.”
Are you disappointed by this news? It does resemble somewhat the director’s stint on True Detective, directing season one to huge acclaim and then not returning for its divisive second season. That being said, there is also the small matter of Bond 25, which he recently signed on to direct for release in 2020.
SEE ALSO: New trailer and images for Maniac starring Jonah Hill and Emma Stone
Set in a world somewhat like our world, in a time quite similar to our time, Cary Joji Fukunaga’s Maniac tells the stories of Annie Landsberg (Emma Stone) and Owen Milgrim (Jonah Hill), two strangers drawn to the late stages of a mysterious pharmaceutical trial, each for their own reasons. Annie’s disaffected and aimless, fixated on broken relationships with her mother and her sister; Owen, the fifth son of wealthy New York industrialists, has struggled his whole life with a disputed diagnosis of schizophrenia. Neither of their lives have turned out quite right, and the promise of a new, radical kind of pharmaceutical treatment—a sequence of pills its inventor, Dr. James K. Mantleray (Justin Theroux), claims can repair anything about the mind, be it mental illness or heartbreak—draws them and ten other strangers to the facilities of Neberdine Pharmaceutical and Biotech for a three-day drug trial that will, they’re assured, with no complications or side-effects whatsoever, solve all of their problems, permanently.
